Project description:MLS000408882-01 and MLS000573813-01 were identified through a cell based screen that measures the reactivation of an epigenetically silenced transgene. MLS000408882-01 and MLS000573813-01 shows selectivity for cancer vs. normal cells affecting both transcriptional patterns and cell viability in a cancer specific manner.
Project description:To investigate global changes in gene expression patterns following treatment with DSCG or MCS-01 we performed RNA-sequencing and nanostring profiling analyses on Day 10 wounds. Differential expression analysis on pre-MCS-01 samples compared to blank identified 649 significantly altered genes at p value <0.05 and absolute fold change >=2. Similarly, in post-MCS-01 samples 954 genes were differentially expressed, of which 566 were down- and 388 up-regulated. DCSG treatment resulted in differential expression of 91 genes. RT-qPCR corroborated increased expression of NFκB and STAT3 with post-MCS-01 treatment. In addition, we compared miRNA expression between MCS-01 samples and controls. Pre-treatment significantly altered expression of 11 miRNAs, while post-treatment altered expression of 28 miRNAs. RT-qPCR confirmed miR-34c upregulation, while significant inverse correlations were found between miR-34c and selected target genes Lef-1, Myb, and Mycn.
